GRI Bio, Inc. (GRI) Fair Value 2026

GRI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, GRI Bio, Inc. (GRI) trades at $1.92. QOC: 4.1/10. Value Trap Risk: 21/100 (SAFE). 0/13 models active.

Key Facts

Ticker
GRI
Price
$1.92
Quality Score
4.1/10
Value Trap Risk
21/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.1/10 signals weak fundamentals

What Fair Value Does Each Model Give GRI?

0 Intrinsic Value Models vs. Current Price ($1.92)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is GRI Bio, Inc. (GRI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, GRI Bio, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About GRI?

0 of 13 models are currently active for GRI. See which stocks rank higher →

How Does GRI Rank in Biotechnology?

Among 625 Biotechnology stocks, GRI ranks #521 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

GRI Bio, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is GRI a Value Trap?

CirclFi's Value Trap algorithm assigns GRI a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for GRI Bio, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, GRI Bio, Inc. scores 4.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GRI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy GRI Bio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MTNBMatinas BioPharma Holdings, Inc.QOC 4.1XRTXXORTX Therapeutics Inc.QOC 4.1TVRDTvardi Therapeutics, Inc.QOC 4.1MTVAMetaVia Inc.QOC 4.1GTBPGT Biopharma, Inc.QOC 4.1ACTUActuate Therapeutics, Inc. Common stockQOC 4.1IDYAIDEAYA Biosciences, Inc.QOC 6.9EQEquillium, Inc.QOC 5.6DMRADamora Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MTNB · XRTX · TVRD · MTVA · GTBP · ACTU · IDYA · EQ · DMRA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to GRI?

5 companies across all industries closest to GRI’s Quality of Company score of 4.1/10.

VYNDVynleads, Inc.QOC 4.1MITIMitesco, Inc.QOC 4.1ARRTArtisan Consumer Goods, Inc.QOC 4.1DXFEason Technology LimitedQOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VYND · MITI · ARRT · DXF · NVDA

Where Does GRI Sit in CirclFi's Biotechnology Rankings?

GRI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About GRI Bio, Inc.’s Valuation?

What is GRI Bio, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for GRI Bio, Inc. (GRI). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GRI overvalued or undervalued right now?

At $1.92, 0 of 0 active models suggest GRI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits GRI Bio, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for GRI?

GRI Bio, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on GRI?

CirclFi analyzes GRI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is GRI a value trap in 2026?

GRI Bio, Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns GRI Bio, Inc. (GRI) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/GRI/ · Methodology
Primary sources for this GRI valuation
  • Financial statements: GRI Bio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001824293) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GRI as of ; valuations recomputed .